Abstracts tagged "Disease Activity"

Abstract Number: 2148 • ACR Convergence 2025
Initial MRI Findings as Predictors of Disease Phenotype in Juvenile Dermatomyositis: A Comparative Study of Myositis Specific Antibodies NXP2-Positive and Myositis Specific Antibody-Negative Patients in a Large Tertiary Hospital
Juan Torres Sanchez¹, Pritish Bawa², Andrea Ramirez¹, MaiLan Nguyen³, Amit Thakral⁴, Xiaofan Huang¹, J Herman Kan² and Marietta De Guzman¹, ¹Baylor College of Medicine, Houston, TX, ²Texas Childrens Hospital, Houston, TX, ³Baylor College of Medicine, Austin, TX, ⁴Texas Children’s Hospital, Houston, TX
Background/Purpose: Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myopathy of childhood, characterized by proximal muscle weakness and distinctive cutaneous findings. Magnetic resonance imaging…
Abstract Number: 1566 • ACR Convergence 2025
Factors Associated with Patient and Physician Global Assessments in Early Systemic Sclerosis
Ellen Romich¹, Alexis Ogdie², Peter Merkel³, Alisa Stephens Shields³, Jessica Alvey⁴, Shervin Assassi⁵, Elana Bernstein⁶, Sonali Bracken⁷, Flavia Castelino⁸, Lorinda Chung⁹, Luke Evnin¹⁰, Tracy Frech¹¹, Jessica Gordon¹², Faye Hant¹³, Monica Harding¹⁴, Laura Hummers¹⁵, Dinesh Khanna¹⁶, Kimberly Lakin¹², Dorota Lebiedz-Odrobina¹⁴, Yiming Luo⁶, Ashima Makol¹⁷, Maureen Mayes¹⁸, Zsuzsanna McMahan¹⁹, Jerry Molitor²⁰, Duncan Moore²¹, Carrie Richardson²², Ami Shah¹⁵, Ankoor Shah²³, Brian Skaug²⁴, Virginia Steen²⁵, John VanBuren¹⁴, Elizabeth Volkmann²⁶, Carleigh Zahn¹⁶ and Nora Sandorfi³, ¹University of Pennsylvania, Media, PA, ²Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ³University of Pennsylvania, Philadelphia, PA, ⁴Utah Data Coordinating Center, University of Utah, Salt Lake City, UT, ⁵Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁶Columbia University, New York, NY, ⁷Duke University Medical Center, Durham, NC, USA, Apex, NC, ⁸Massachusetts General Hospital, Boston, MA, ⁹Stanford University, Stanford, CA, ¹⁰Scleroderma Research Foundation, San Francisco, CA, ¹¹Vanderbilt University Medical Center, Nashville, TN, ¹²Hospital for Special Surgery, New York, NY, ¹³Medical University of South Carolina, Charleston, SC, ¹⁴University of Utah, Salt Lake City, UT, ¹⁵Johns Hopkins Rheumatology, Baltimore, MD, ¹⁶University of Michigan, Ann Arbor, MI, ¹⁷Mayo Clinic, Rochester, MN, ¹⁸UT Health Houston Division of Rheumatology, Houston, TX, ¹⁹UT Health Houston, Houston, TX, ²⁰University of Minnesota, Minneapolis, MN, ²¹Northwestern Memorial Hospital, Chicago, IL, ²²Northwestern University, Chicago, IL, ²³Duke University, Durham, NC, ²⁴UTHealth Houston Division of Rheumatology, Houston, TX, ²⁵Georgetown University School of Medicine, Washington, DC, ²⁶Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA
Background/Purpose: Global assessments by patients and physicians provide unique but complementary perspectives of disease severity. This study aimed to determine the clinical and patient-reported factors…
Abstract Number: 1411 • ACR Convergence 2025
Defining Minimal Disease Activity (MDA) in Psoriatic Arthritis (PsA) with the inclusion of Psoriatic Arthritis Impact of Disease (PsAID) scores rather than Health Assessment Questionnaire (HAQ)
Conor Coyle¹, Sarah Yazji², Sruthi Murthy³, Philip Helliwell⁴, Andra Balanescu⁵, Juan Cañete⁶, Emmanuelle Dernis⁷, Uta Kiltz⁸, Ying Ying Leung⁹, Ana-Maria Orbai¹⁰, PENELOPE PALOMINOS¹¹, Josef Smolen¹², Maarten de Wit¹³, Laure Gossec¹⁴ and Laura Coates¹⁵, ¹Oxford University Hospitals, Reading, United Kingdom, ²South Texas Health System GME Consortium, Texas A&M College of Medicine, Texas, USA, College Station, TX, ³Oxford University Hospitals NHS Foundation Trust, Oxford, UK, Oxford, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ⁵UNIVERSITY OF MEDICINE AND PHARMACY CAROL DAVILA, Bucharest, Romania, ⁶Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ⁷Rheumatology Department, Le Mans Central Hospital, Le Mans, France, LE MANS, France, ⁸Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁹Rheumatology Department, Singapore General Hospital, Singapore, Singapore, Singapore, Singapore, ¹⁰Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹¹Hospital Lifeplus Litoral Norte, Xangri-lá, Brazil, Porto Alegre, Rio Grande do Sul, Brazil, ¹²Division of Rheumatology, Department of Medicine ³, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ¹³Patient Research Partner, Stichting Tools, Amsterdam, Netherlands, ¹⁴Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ¹⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Treat to target management is recommended in psoriatic arthritis (PsA) to improve disease control and patient quality of life. Minimal disease activity (MDA) criteria…
Abstract Number: 1218 • ACR Convergence 2025
Social Determinants Shape Health Outcomes in Idiopathic Inflammatory Myopathies: Insights from Lived Experience of 1,252 Patients
Tsvetelina Velikova¹, Kostadin Kostadinov², Emilia Naseva³, Tamar Rubinstein⁴, Manali Sarkar⁵, Lavanya Mangla⁶, Joanna Makowska⁷, Raphael Micheroli⁸, Leandro ferreryra⁹, Linda Kobert¹⁰, Ioannis Parodis¹¹, Elena Nikiphorou¹², Samuel Shinjo¹³, Carlo Vinicio Caballero Uribe¹⁴, Vincenzo Venerito¹⁵, Vikas Agarwal¹⁶ and Latika Gupta¹⁷, ¹Medical Faculty, Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ²Department of Social Medicine and Public Health, Faculty of Public Health, Medical University, Plovdiv; Health and Quality of Life in a Green and Sustainable Environment Research Group, Strategic Research and Innovation Program for the Development of MU- Plovdiv, Medical University of Plovdiv, Environmental Health Division, Research Institute at Medical University of Plovdiv, Medical University of Plovdiv,, Plovdiv, Bulgaria, ³Faculty of Public Health, Medical University of Sofia, ¹⁵ Acad. Ivan Evstratiev Geshov, ¹⁶⁰⁶ Sofia; Medical Faculty, Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ⁴Albert Einstein College of Medicine, White Plains, NY, ⁵Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India., Mumbai, Maharashtra, India, ⁶Maulana Azad Medical College, ²-Bahadurshah Zafar Marg, New Delhi, New Delhi, India, ⁷Department of Rheumatology, Medical University of Lodz, Lodz, Poland, ⁸University Hospital Zurich, Zurich, Switzerland, ⁹HIBA, CABA, Ciudad Autonoma de Buenos Aires, Argentina, ¹⁰The Myositis Association, Columbia, MD, ¹¹Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ¹²King's College London, London, United Kingdom, ¹³Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ¹⁴Department of Medicine, Hospital Universidad del Norte, Barranquilla, Atlantico, Colombi, Barranquilla, Colombia, ¹⁵Univeristy of Bari "Aldo Moro", Italy, Bari, Bari, Italy, ¹⁶Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁷School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom
Background/Purpose: The impact of social determinants of health (SDoH)—including socioeconomic status, social support, and geographic context—on disease outcomes in idiopathic inflammatory myopathies (IIM) remains underexplored.…
Abstract Number: 0552 • ACR Convergence 2025
Radiographic Sacroiliitis Progression in Psoriatic Arthritis
Virginia Carrizo Abarza¹, Pankti Mehta², Fadi Kharouf³, Shangyi Gao⁴, Dafna D. Gladman⁵, Vinod Chandran⁶ and Denis Poddubnyy⁷, ¹Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ²University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ³University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁴Gladman-Krembil Psoriatic Arthritis Research Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: Radiographic sacroiliitis is an important indicator of axial involvement psoriatic arthritis (PsA), but only little is known about factors associated with progression of sacroiliitis.…
Abstract Number: 0488 • ACR Convergence 2025
Early and Sustained Improvements in Disease Activity and Patient-Reported Outcomes in Patients Treated with Filgotinib for Rheumatoid Arthritis: Up to 2-Year Interim Real-World Data From FILOSOPHY and PARROTFISH
Jérôme Avouac¹, Neil Betteridge², Karen Bevers³, Gerd Burmester⁴, Roberto Caporali⁵, Ouafia Bouzid⁶, Thomas Debray⁶, Carole Van der Donckt⁶, James Galloway⁷, Susana Romero-Yuste⁸ and Patrick Verschueren⁹, ¹Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ²Neil Betteridge Associates, London, United Kingdom, ³Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁵University of Milan and ASST Gaetano Pini-CTO, Milano, Italy, ⁶Alfasigma S.p.A., Bologna, Italy, ⁷King's College London, London, United Kingdom, ⁸University Hospital Complex of Pontevedra, Pontevedra, Spain, ⁹Rheumatology, University Hospital Leuven and Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium
Background/Purpose: FILOSOPHY (NCT04871919) and PARROTFISH (NCT05323591) are ongoing, prospective, observational Phase 4 studies of filgotinib in patients (pts) with rheumatoid arthritis (RA) in Europe. In…
Abstract Number: 0380 • ACR Convergence 2025
Multidimensional Health Assessment Questionnaire (MDHAQ)/RAPID3, is an Useful Tool to Assess Comorbid and Residual Fatigue in Rheumatoid Arthritis Patients
Rosa Maria Morlà Novell¹, Beatriz Frade Sosa², Maria López-Lasanta³, Meritxell Sallés Lizarzáburu⁴, Noemí Busquets Pérez⁵, Georgina Salvador Alarcón⁶, Marta Valls Roc⁷, Virginia Ruiz-Esquide⁸, Lola Tobalina Mastre⁹, Raimon Sanmartí⁸ and José Gomez-Puerta¹⁰, ¹Hospital Clínic de Barcelona, Barcelona, Spain, ²Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ³Hospital Universitari Vall d´Hebron, Barcelona, Spain, ⁴Xarxa Sanitària Althaia Manresa, Manresa, Spain, ⁵Hospital de Granollers, Granollers, Spain, ⁶Hospital Universitari Mùtua Terrassa, Terrassa, Spain, ⁷Hospital Universitari Dr Trueta, Girona, Sudan, ⁸Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ⁹IDIBAPS. Hospital Clinic de Barcelona, Barcelona, ¹⁰Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain
Background/Purpose: Fatigue is a highly prevalent (40%-70%)1 comorbidity in rheumatoid arthritis (RA) patients, and residual fatigue has been described in a significant proportion of patients…
Abstract Number: 2654 • ACR Convergence 2025
Discordance Between Patient and Physician Global Assessments in Early Systemic Sclerosis
Ellen Romich¹, Alexis Ogdie², Alisa Stephens Shields², Peter Merkel², Jessica Alvey³, Shervin Assassi⁴, Elana Bernstein⁵, Sonali Bracken⁶, Flavia Castelino⁷, Lorinda Chung⁸, Luke Evnin⁹, Tracy Frech¹⁰, Jessica Gordon¹¹, Faye Hant¹², Monica Harding¹³, Laura Hummers¹⁴, Dinesh Khanna¹⁵, Kimberly Lakin¹¹, Dorota Lebiedz-Odrobina¹³, Yiming Luo⁵, Ashima Makol¹⁶, Maureen Mayes¹⁷, Zsuzsanna McMahan¹⁸, Jerry Molitor¹⁹, Duncan Moore²⁰, Carrie Richardson²¹, Ami Shah¹⁴, Ankoor Shah²², Brian Skaug²³, Virginia Steen²⁴, John VanBuren¹³, Elizabeth Volkmann²⁵, Carleigh Zahn¹⁵ and Nora Sandorfi², ¹University of Pennsylvania, Media, PA, ²University of Pennsylvania, Philadelphia, PA, ³Utah Data Coordinating Center, University of Utah, Salt Lake City, UT, ⁴Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁵Columbia University, New York, NY, ⁶Duke University Medical Center, Durham, NC, USA, Apex, NC, ⁷Massachusetts General Hospital, Boston, MA, ⁸Stanford University, Stanford, CA, ⁹Scleroderma Research Foundation, San Francisco, CA, ¹⁰Vanderbilt University Medical Center, Nashville, TN, ¹¹Hospital for Special Surgery, New York, NY, ¹²Medical University of South Carolina, Charleston, SC, ¹³University of Utah, Salt Lake City, UT, ¹⁴Johns Hopkins Rheumatology, Baltimore, MD, ¹⁵University of Michigan, Ann Arbor, MI, ¹⁶Mayo Clinic, Rochester, MN, ¹⁷UT Health Houston Division of Rheumatology, Houston, TX, ¹⁸UT Health Houston, Houston, TX, ¹⁹University of Minnesota, Minneapolis, MN, ²⁰Northwestern Memorial Hospital, Chicago, IL, ²¹Northwestern University, Chicago, IL, ²²Duke University, Durham, NC, ²³UTHealth Houston Division of Rheumatology, Houston, TX, ²⁴Georgetown University School of Medicine, Washington, DC, ²⁵Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA
Background/Purpose: To determine the frequency and extent of discordance between patient and physician global assessments of disease in early systemic sclerosis and identify factors associated…
Abstract Number: 2347 • ACR Convergence 2025
Bimekizumab Treatment Resulted in Patients with Axial Spondyloarthritis Maintaining Their Clinical Responses Over 3 Years: Results from Two Phase 3 Studies and Their Open-Label Extension
Fabian Proft¹, Désirée Van Der Heijde², Sergio Schwartzman³, Vanessa Taieb⁴, Sarah Kavanagh⁵, Gaëlle Varkas⁶, Victoria Navarro-Compan⁷ and Xenofon Baraliakos⁸, ¹Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Weill Cornell Medical Center, New York Presbyterian Hospital, and Hospital for Special Surgery, New York, NY, ⁴UCB, Colombes, France, ⁵UCB, Morrisville, NC, ⁶Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁷Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁸Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease which requires optimal management.1 In clinical trials, Assessment of SpondyloArthritis international Society ≥40% improvement (ASAS40) is…
Abstract Number: 2131 • ACR Convergence 2025
Transition from Juvenile Dermatomyositis to Spondyloarthritis: A Novel Overlapping Inflammatory Phenotype
Austen Grooms¹, Ioannis Karageorgiou², Kerry Mychaliska² and James Birmingham³, ¹William Beaumont University Hospital, Auburn Hills, MI, ²William Beaumont University Hospital, Royal Oak, MI, ³River City Rheumatology, Grand Rapids, MI
Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare inflammatory disease primarily affecting muscle, skin, and vasculature. Characterized by muscle weakness, distinctive skin lesions, and autoantibodies, it…
Abstract Number: 1550 • ACR Convergence 2025
Real-World Outcomes of Anifrolumab in Systemic Lupus Erythematosus Patients at Toronto Lupus Program
Virginia Carrizo Abarza¹, Qixuan Li², Teresa Semalulu³, Justin Smith³, Pankti Mehta⁴, Fadi Kharouf⁵, Dafna D. Gladman⁶, Laura Whitall Garcia⁷ and Zahi Touma³, ¹Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ⁵University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁷University Health Network, Toronto, ON, Canada
Background/Purpose: Anifrolumab (ANI) is a human monoclonal antibody targeting the type I interferon receptor subunit 1 (IFNAR1), blocking interferon activity and reducing disease activity in…
Abstract Number: 1410 • ACR Convergence 2025
Examining the Interchangeability of Two Different Patient-Reported Global Assessment Measures in an Observational Axial Spondyloarthritis Cohort
Connor Vershel¹, Mark Hwang², John Reveille³, Seokhun Kim⁴, Matthew A. Brown⁵, Michael Weisman⁶, Mariko Ishimori⁶ and Michael Ward⁷, ¹Department of Internal Medicine, Division of Rheumatology, John P. and Katherine G. McGovern School of Medicine at the University of Texas Health Science Center at Houston, Houston, TX, ²UTHealth Houston, Houston, TX, ³Department of Medicine, University of Texas Medical Center, Houston, TX, ⁴UTHealth Houston, Houston, ⁵Genomics England, London, United Kingdom, ⁶Cedars-Sinai Medical Center, LOS ANGELES, CA, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD
Background/Purpose: In axial spondyloarthritis cohorts, patient reported outcomes are vital for tracking disease progression and response to therapy. However, many cohorts enrolled prior to the…
Abstract Number: 1212 • ACR Convergence 2025
Relapse in Idiopathic Inflammatory Myopathies: insights from extended MyoCite and Italian Consortia
Maria Rosa Pellico¹, Cristina Bochicchio², Claudia Iannone³, Lekshmi Minikumari Rahulan⁴, Marco Fornaro⁵, Ilaria Cavazzana⁶, Edoardo Conticini⁷, Masataka Kuwana⁸, Akira Yoshida⁹, Silvia Cavalli², Silvia Grazzini⁷, Alessia Gatti¹⁰, Giulio Lopinto¹¹, Paolo Semeraro¹², Thomas Patrick Sheeran¹³, Florenzo Iannone¹⁴, Vikas Agarwal¹⁵, Roberto Caporali¹⁶, Nicoletta Del pAPA¹ and Latika Gupta¹⁷, ¹ASST Pini-CTO, Clinical Rheumatology Unit, Milano, Italy, ²ASST Pini-CTO, Clinical Rheumatology Unit, Milan, Italy, ³University of Milan, Gaetano Pini CTO, Milano, Milan, Italy, ⁴Sanjay Gandhi Postgraduate Institute of Medical sciences Lucknow, Lucknow, Uttar Pradesh, India, ⁵Unit of Rheumatology, Department of Precision and Regenerative Medicine, Area Jonica (DiMePRe-J), University of Bari, Italy., Bari, Italy, ⁶Rheumatology and Clinical Immunology Unit, Clinical and Experimental Sciences Department, ERN ReCONNET, ASST Spedali Civili of Brescia and University of Brescia, Brescia, Italy, Brescia, Lombardia, Italy, ⁷Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Italy, Siena, Italy, ⁸Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁹Department of Allergy and Rheumatology Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ¹⁰Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili and University of Brescia, Brescia, Lombardia, Italy, ¹¹Unit of Rheumatology, Department of Precision and Regenerative Medicine, Area Jonica (DiMePRe-J), University of Bari, Italy., Bari, ¹²Rheumatology and Clinical Immunology Unit, Clinical and Experimental Sciences Department, ERN ReCONNET, ASST Spedali Civili of Brescia and University of Brescia, Brescia, Italy, Brescia, Italy, ¹³Department of Rheumatology, The Royal Wolverhampton NHS Trust, Wolverhampton, UK; Rheumatology Department, Walsall Manor Hospital, Walsall, UK, Wolverhampton, United Kingdom, ¹⁴Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, ¹⁵Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁶University of Milan and ASST Gaetano Pini-CTO, Milano, Italy, ¹⁷School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of rare and heterogeneous diseases. One of the greatest challenges in IIM management is defining and predicting…
Abstract Number: 0892 • ACR Convergence 2025
Relapse and Immune Dysregulation in Giant Cell Arteritis Are Linked to Mosaic Loss of the Y Chromosome
Simon M. Petzinna, Sophie-Marie Kirch, Maike S. Adamson, De Xi, Claus-Jürgen Bauer, Lena Kreis, Pantelis Karakostas, Rayk Behrendt, Sebastian Zimmer, Raul N. Jamin and Valentin S. Schäfer, University Hospital Bonn, Bonn, Nordrhein-Westfalen, Germany
Background/Purpose: Mosaic loss of the Y chromosome (mLOY) is the most common acquired somatic mutation. Epidemiological studies have linked mLOY to malignancies, as well as…
Abstract Number: 0487 • ACR Convergence 2025
Efficacy of sarilumab in patients with rheumatoid arthritis of different disease activity at treatment initiation: a post-hoc analysis of a Phase 3 trial of sarilumab in Japan
Hideto Kameda¹, Toshiya Takahashi², Naoki Soeda² and Yoshiya Tanaka³, ¹Department of Internal Medicine, Toho University, Tokyo, Japan, ²Medical Affairs, Asahi Kasei Pharma Corporation, Tokyo, Japan, ³University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: The efficacy and safety of sarilumab (SAR) and methotrexate (MTX) in patients (pts) in Japan with moderate-to-severely active rheumatoid arthritis (RA) and inadequate response…

« Previous Page
1
…
4
5
6
7
8
…
112
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].